CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|March 1, 2009
Formulary Digital Edition March 2009
Review of common sexually transmitted diseases; Focus on ustekinumab; Drug Watch: Agents in late-stage development for the treatment of pulmonary diseases
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Billing for lab tests, especially genetic tests, is a mess. Bill Kerr has ideas about how to clean it up.
2
A conversation with Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, about the relationship between HIV incidence in Hispanic communities and immigration policy
3
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
4
Closing the outpatient monitoring gap in cancer
5